The Cystic Fibrosis Foundation is employing Artificial Intelligence to develop new therapies for cystic fibrosis (CF). They are collaborating with Antiverse to design antibody drugs targeting the notoriously difficult cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Traditional methods struggle to target membrane proteins like CFTR due to their small, dynamic structures. Antiverse's AI-driven platform, combining generative models and rapid experimental validation, can design epitope-specific antibodies in under four months, a significant acceleration from the one-to-two-year timelines for conventional discovery.
This partnership highlights investor confidence in AI's potential for therapeutic antibody development. Antiverse is also pursuing treatments for oncology and central nervous system disorders.